Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF) @NEJMgroup
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF) @NEJMgroup
Uploaded August 2026 | Updated September 2026, 1 week ago
In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation.

Read the full SINGLE-AF trial results at NEJM.org.

#esccongress #cardiology #nejm | @EuropeanSocietyofCardiology
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF)NEJM Outbreaks Updates — Andes HantavirusNEJM This Week — August 13, 2026Dr. Glaucomflecken Explains: Transdermal Estradiol in Prostate CancerBiDil — The Story of the Black PillImage Challenge — May 7, 2026High-Reliability Organizing: Refreshing a Proven Framework for Modern Health Care ChallengesClinical Practice: Prevention and Treatment of Peanut AllergyDr. Glaucomflecken Explains: Rituximab versus Ocrelizumab in Relapsing Multiple SclerosisCould a Low-Plastic Lifestyle Lower Plastic Levels in our Body?Three Studies That Made Headlines in MayClinical Practice: Fibromyalgia
NEJM Group |

Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER